Gaush Meditech Ltd

Gaush Meditech Ltd has a fully diluted share count of 147,887,869 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible instruments. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

The company reported a last actual EPS of 1.29 CNY and a last actual revenue of 1,554,572,000 CNY. These figures will be compared to industry_config preferred metrics and cohort medians in the next section.

Gaush Meditech Ltd's revenue is derived from the sale and distribution of medical equipment and supplies, with no disclosed segment or geographic breakdown in the available data. The lack of segmental or geographic detail limits the ability to assess revenue concentration or exposure to specific markets.

The company's growth trajectory is not quantified in the available data, as no outlook numeric deltas or revenue history beyond the last actual revenue are provided. Analysts will need to monitor future filings for more detailed revenue trends and guidance.

The risk assessment indicates a low dilution potential, with no significant dilution sources identified in the available data. However, the absence of balance-sheet inputs and going-concern language prevents a full liquidity risk assessment.

Recent events, including filings and transcripts, are not detailed in the available data, limiting the ability to assess any recent strategic or operational developments.

Revenue ¥1.38B, −3,4% YoY; Operating income −30,1% YoY.

• ▍Revenue ¥1.38B, −3,4% YoY
• ▍Operating income −30,1% YoY
• ▍Net income +4,1% YoY
• ▍Net margin 7.0%

Revenue ¥1.43B, +1,6% YoY; Operating income −35,6% YoY.

• ▍Revenue ¥1.43B, +1,6% YoY
• ▍Operating income −35,6% YoY
• ▍Net income −46,8% YoY
• ▍Free cash flow −129,2% YoY
• ▍Net margin 6.5%